

# Optimization Of Oxygen Titration and Weaning With FreeO<sub>2</sub>: Update On Clinical Evaluation In More Than 700 subjects

François Lellouche<sup>1,3</sup>, Pierre-Alexandre Bouchard<sup>1</sup>, Erwan L'Her<sup>2,3</sup>

<sup>1</sup>Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, Canada, <sup>2</sup>CHU La Cavalle Blanche, Université Bretagne Occidentale, Brest, France, <sup>3</sup>Oxynov, Inc, Québec, Canada

## Introduction

The first goal of oxygen therapy is to avoid hypoxemia. However, excessive oxygen flow rate may be detrimental through toxicity and prolonged oxygen therapy. Oxygen toxicity was described by Lavoisier himself in 1783 with acute respiratory failure occurring in guinea pigs with pure oxygen within few days (1). Lorrain Smith and other authors confirmed this direct pulmonary toxicity (2). Hyperoxia-induced hypercapnia in severe COPD patients (3) and proliferative retinopathy (4) are known for almost 70 years. Beyond this well-known toxicity, a global and systemic toxicity of oxygen related to diffuse arterial vasoconstriction (5) and inflammation is now well described. A recent meta-analysis confirmed the impact on mortality (6) and dose effect of oxygen toxicity seems well demonstrated (7). The recommendations concerning oxygen administration are well defined: titration of oxygen to maintain SpO<sub>2</sub> within a accurate range 88-92% in COPD and hypercapnic patients and 94-98% in other patients with close monitoring (8). These recommendations are not followed and automated oxygen titration may be useful. We developed and evaluated a new device developed to automatically titrate oxygen flowrate based on SpO<sub>2</sub> target set by the clinicians (FreeO<sub>2</sub>, Oxynov, Canada). We present an update of the clinical evaluation of this device.


**References:** 1- Lavoisier 1783. 2- Lorrain Smith 1899. 3- Davis Lancet 1949 4- Terry Am J Ophthalmology 1942 5- Poder BMJ open 2018. 6- Chu Lancet 2018. 7- Helmerhorst CCM 2017 8- O'Driscoll BTS guidelines 2017

## Methods

FreeO<sub>2</sub> is an automated system which automatically adjusts the administered O<sub>2</sub> flow using a closed-loop algorithm, based on physiological data (mainly SpO<sub>2</sub> measured every second) and provides continuous monitoring of cardio-respiratory parameters.

A proportional integral controller adjusts the oxygen flow delivered by a mass-flow controller from 0 to 20 L/min (accuracy 0.1 L/min), with the aim of maintaining the SpO<sub>2</sub> within a predefined target that can be set by the clinicians.

FreeO<sub>2</sub> was compared to usual administration of O<sub>2</sub>, in randomized controlled studies, with two parallel arms or with a cross over design.



FreeO<sub>2</sub> has been evaluated in more than 700 patients, only completed studies are presented here.

## Results

n	Population	Study design = RCT	Main results with FreeO <sub>2</sub>
10	Healthy Subjects <sup>1</sup> Spont. Breathing	FreeO <sub>2</sub> vs. Air vs. continuous O <sub>2</sub>	↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia ↓ induced tachycardia
10	Healthy Subjects SB, CPAP, NIV	FreeO <sub>2</sub> vs. Air vs. continuous O <sub>2</sub>	↑ time in the SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia ↓ workload with FreeO <sub>2</sub>
16	COPD Rehabilitation <sup>2</sup>	FreeO <sub>2</sub> vs. Air vs. continuous O <sub>2</sub>	↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia ↑ exercise tolerance vs. air (p<0.05) and vs. O <sub>2</sub> (trend p=0.22)
12	Severe COPD on LTOT Rehabilitation <sup>3</sup>	FreeO <sub>2</sub> vs. continuous O <sub>2</sub>	↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia ↑ exercise tolerance vs O <sub>2</sub> (p=0.02), no induced hypercapnia
50	COPD Hospitalization for AE <sup>4</sup>	FreeO <sub>2</sub> vs. continuous O <sub>2</sub> (manual setting)	FreeO <sub>2</sub> well accepted by caregivers and patients ↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia 30% reduction in hospital LOS (p=0.051)
47	COPD Hospitalization for AE <sup>5</sup>	Economic evaluation Cost analysis and ICERs	-20.7% /patient costs reduction (-Can\$ 2,959.71; p=0.13) ICERs = -Can\$ 96.91 per % point in the target SpO <sub>2</sub>
190	ARF in the ED <sup>6</sup>	FreeO <sub>2</sub> vs. continuous O <sub>2</sub> (manual setting)	↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia ↑ Patients O <sub>2</sub> weaned, ↓ hospital LOS
60	Acute coronary syndrome <sup>7</sup>	FreeO <sub>2</sub> (target 92%) FreeO <sub>2</sub> (target 96%) vs. manual O <sub>2</sub> setting	↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia Less ventricular arrhythmias
60	Broncholitis ARF <sup>8</sup>	FreeO <sub>2</sub> vs. manual O <sub>2</sub> setting	↑ time in SpO <sub>2</sub> target, ↓ hypoxemia, ↓ hyperoxia, ↓ hospital LOS

**Table references:** 1- Lellouche & L'Her. Respiratory Care 2012;57(8):1254-62. 2- Lellouche et al. Respiratory care 2016;61:1456-64. 3- Vivodtzev et al. European Respiratory Journal 2016;48:1567 4- Lellouche et al. International journal of chronic obstructive pulmonary disease 2016;11:1983-90 5- Poder et al. BMJ open 2018;8:e018835. 6- L'Her et al. Eur Respir J. 2017 Jul 20;50(1). 7- Huynh Ky et al AJRCCM 2017;195:A3766 8- Barzic et al. Thesis 2016

## Conclusions

The main findings of these studies can be summarized as follow:

- Optimized oxygenation <sup>1,2,3,4, 5,6,7,8</sup>:
  - (1) increase of the time within SpO<sub>2</sub> target (above 80% of the time with FreeO<sub>2</sub> compared to about 50% with manual titration. In the pediatric study, the time in the target was 95%
  - (2) Reduction of the time with hypoxemia
  - (3) Reduction of the time with hyperoxia
- Automated weaning of oxygen → Reduced oxygen therapy duration <sup>4,5,6</sup>
- Reduced length of the hospital stay (-30%) associated with a reduction of the costs during acute exacerbation of COPD <sup>4,5</sup>
- Automated triage (at the emergency department)
- Increased exercise tolerance: in COPD patients, oxygenation was improved (less hypoxemia and less hyperoxia with automated oxygen titration)<sup>2,3</sup> walking distance was increased<sup>3</sup> and there was no worsening of hypercapnia in most severe patients despite much higher oxygen flow with FreeO<sub>2</sub>

**Grants:** Fonds de Recherche en Santé du Québec, Canadian Foundation for Innovation, IUCPQ foundation, Mitacs Accélération – Oxynov Funding